Comparable stake leader
Injective Foundation
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001938109.
Comparable stake leader
Injective Foundation
Disclosed value leader
Injective Foundation
Comparable rows
2/17
Latest evidence
30 Jun 2026
Ownership snapshot
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Quick read
2 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Injective Foundation |
13D/G
3/4/5
10%+ Owner
|
37%
Reported 13D/G
· 30 Dec 2025
|
$26,346,155
9,615,385 shares
|
$0 | 30 Dec 2025 |
| Kendall Leo Marin |
3/4/5
13D/G
COO, Director, 10%+ Owner · Marin Kendall Leo
|
10%
Reported 13D/G
· 16 Jun 2025
|
$238,209
2,414,736 shares
mixed-class rows
|
— | 16 Jul 2025 |
| Shubha-Jeet Dasgupta |
3/4/5
CEO, Director, 10%+ Owner
|
—
mixed-class rows
|
$2,400
72,638 shares
mixed-class rows
|
— | 16 Jul 2025 |
| Anthony Georgiades |
3/4/5
Director
|
—
denominator unverified
|
$881,578
1,315,789 shares
|
— | 06 Jan 2026 |
| Charles Andrew Green |
3/4/5
Director
|
—
mixed-class rows
|
$671,815
714,400 shares
mixed-class rows
|
— | 16 Jul 2025 |
| Christa Lillian Mitchell |
3/4/5
CSO, Director
|
—
denominator unverified
|
$285,330
279,735 shares
|
— | 01 Aug 2024 |
| XTX Topco Ltd |
13F
Company
|
—
denominator unverified
|
$50,437
49,938 shares
|
— | 30 Jun 2026 |
| Tasis Anastasios Giannoukakis |
3/4/5
Director
|
—
mixed-class rows
|
$48,000
805,023 shares
mixed-class rows
|
— | 16 Jul 2025 |
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 29 Oct 2025.
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Showing 1-10 of 10 reporting-owner rows connected to Pineapple Financial Inc.. Open a relationship link for the CIK-to-CIK filing trail.
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anthony Georgiades | Director | $881,578 | Mixed | 06 Jan 2026 | ||
| Charles Andrew Green | Director | $671,815 | Mixed | 16 Jul 2025 | ||
| Christa Lillian Mitchell | CSO, Director | $285,330 | Filing P/S | 01 Aug 2024 | ||
| Kendall Leo Marin | COO, Director, 10%+ Owner | $238,209 | Market | 16 Jul 2025 | ||
| Tasis Anastasios Giannoukakis | Director | $48,000 | Filing P/S | 16 Jul 2025 | ||
| Nima Besharat | Director | $24,857 | Mixed | 12 Oct 2023 | ||
| Shubha-Jeet Dasgupta | CEO, Director, 10%+ Owner | $2,400 | Filing P/S | 16 Jul 2025 | ||
| Habib Syed Sarfraz | Cfo | Mixed | 16 Jul 2025 | |||
| Paul Robert Maurice Baron | Director | Mixed | 16 Jul 2025 | |||
| Injective Foundation | 10%+ Owner | Mixed | 30 Dec 2025 |
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Anthony Georgiades | PAPL | Common Shares | 0 | 1,315,789 | 06 Jan 2026 | See footnote 1 | ||||
| Injective Foundation | PAPL | Common Shares | 0 | 9,615,385 | 30 Dec 2025 | Direct |